Qarguni gin arqiliq dawalash

Towendiki xewerde eytilishiche Engiliyede qarghuni gen bilen
dawalash haywanda muhapiqiyetlik bolup, ademde sinaq qilish
basquchigha kirgen iken.

Qarghu bolsa hazirgha qeder saqaytish bek qiyin bolghan kisellerning
biri bolup, adem qarghu bolup qalghanda, gerche adem hayatigha
tehdit ekelmisimu, biraq turmush supiti eghir derijide towenley,
bimar bir omur qarangghuluq ichide yashashqa mejburu bolidu.
Qarghuni gin bilen dawalash kelguside kozi kormes bolup
qalghanlargha qaytidin umut nuri ata qilghusi.


UK doctors test gene therapy to treat blindness
Reuters Health

Tuesday, May 1, 2007

LONDON (Reuters) - A team of British doctors has carried out the
world's first eye operations using gene therapy to try to cure a
serious sight disorder, officials said on Tuesday.

The group from Moorfields Eye Hospital and University College London
(UCL) has operated on a small number of young adults with Leber's
congenital amaurosis, a type of inherited childhood blindness caused
by a single abnormal gene.

The condition prevents the retina from detecting light properly,
resulting in progressive deterioration and severely impaired
eyesight. There is no effective treatment.

The new experimental procedure involves inserting normal copies of
the faulty RPE65 gene into cells of the retina -- the light-
sensitive layer of cells at the back of the eye -- using a harmless
virus or vector.

The British doctors are working alongside Seattle, Washington-based
biotech firm Targeted Genetics Corp., which made the vector being
used in the Phase I/II trial.

It will be several months before the success of the procedure can be
properly assessed but medics said there had been no complications so
far.

The move into human testing follows 15 years of laboratory and
animal experimentation, including tests on dogs whose vision was
restored to the extent they could navigate a maze with ease.
"Testing it for the first time in patients is very important and
exciting and represents a huge step towards establishing gene
therapy for the treatment of many different eye conditions," Robin
Ali, professor of human molecular genetics at UCL, said in a
statement.

The clinical trial was given 1 million pounds ($2 million) of
funding by Britain's Department of Health, which said the pioneering
research underlined the country's leading position in gene therapy
in Europe.

The idea of using gene therapy to fix diseases caused by genetic
faults has long appealed to scientists, although getting the idea to
work in practice has proved tricky.

Some gene therapy approaches have helped patients. But one 18-year-
old volunteer died in a gene therapy experiment in 1999 and two
French boys cured of a rare immune disease later developed
leukaemia.

Over 70 percent of gene therapy trials to date have been for cancer,
where the process is complicated by the need to reach multiple sites
in the body.

The eye, by contrast, is relatively straightforward, said Andrew
George of London's Imperial College.

"The eye is good for gene therapy because it is a simple organ and
it is easy to see what is going on. There is hope that once gene
therapy is developed in the eye, scientists could move on to more
complex organs," he said.

Reuters Health